Objective To evaluate the differences of the malignant rate of thyroid nodules between primary hyperparathyroidism (PHPT) patients and health examination population, and analyze the clinical characteristics of PHPT combined with papillary thyroid carcinoma (PTC). Methods The clinical data of 158 PHPT patients who had underwent parathyroidectomy and 468 thyroid nodule patients who had underwent fine-needle aspiration (FNA) from 2009 to 2014 were retrospectively analyzed, and the detection rate of PTC in patients with thyroid nodule was recorded. Results Of the 158 patients with PHPT, 61 patients had thyroid nodules, the incidence of PHPT with thyroid nodule was 38.6% (61/158), and postoperative pathologically proved PTC was in 12 cases (19.7%). Of the 468 thyroid nodule patients who had underwent FNA, postoperative pathologically proved PTC was in 19 patients (4.1% ). The malignant rate of thyroid nodules in PHPT patients was significantly higher than that in health examination population (P＜0.01). The adjusted serum calcium in patients with PHPT combined with PCT was significantly lower than that in patients with PHPT combined with benign thyroid nodules and patients with PHPT without thyroid nodules: (2.63 ± 0.26) mmol/L vs. (2.92 ± 0.32) and (2.93 ± 0.47) mmol/L, and there was statistical difference (P＜0.05). Conclusions The malignant rate of thyroid nodules in PHPT patients is significantly higher than that in patients from health examination population, which suggests that PHPT might be a risk factor for the malignancy of thyroid nodules. A lower level of serum calcium may predict the existence of PCT in PHPT patients with thyroid nodules.

Objective:To investigate the level of serum Omentin-1 in subjects with abdominal obesity, and to analyze the influencing factors of Omentin-1 and its relationship with body fat distribution, insulin resistance and metabolic parameters.Methods:A retrospective case-control study was conducted to analyze the clinical data of one hundred and fifty adults with abdominal obesity (BMI≥28 kg/m 2) who were randomly selected from Obesity Multidisciplinary Diagnosis and Treatment Center, Subei People's Hospital from Januray 2018 to December 2021. Meanwhile, 150 healthy adults were enrolled as a normal control group. Fasting serum Omentin-1 and glucose metabolism were measured, and homeostasis model assessment of insulin resistance index (HOMA-IR) was calculated. Body fat composition was measured by bioelectrical impedance analysis. The relationship between Omentin-1 and other variables were presented by the Pearson correlation coefficients. Stepwise regression model was used to analyze the influencing factors of Omentin-1. Results:The serum omentin-1 level of patients with abdominal obesity was (36.97±6.99) μg/L, that of normal control group was (72.35±6.09) μg/L. The difference between the two groups was statistically significant ( t=46.69, P<0.001). The body fat level of patients with abdominal obesity was (43.40±14.59) kg, that of normal control group was (13.78±4.13) kg. The difference between the two groups was statistically significant ( t=23.93, P<0.001). The fasting insulin of patients with abdominal obesity was 29.05 (22.01,34.60) pmol/L, that of normal control group was 127.90 (84.08,201.45) pmol/L. The difference between the two groups was statistically significant( Z=14.75, P<0.001). The HOMA-IR of patients with abdominal obesity was 0.87 (0.68,1.05), that of normal control group was 4.19 (2.77,7.31). The difference between the two groups was statistically significant ( Z=14.75, P<0.001). Pearson linear correlation analysis showed that serum omentin-1 levels were negatively correlated with BMI, waist circumference, waist-hip ratio (WHR), body fat, visceral Fat area (VFA), HOMA-IR, triglyceride, total cholesterol and low density lipoprotein cholesterol ( r=-0.825, -0.843, -0.756, -0.777, -0.835, -0.583, -0.429, -0.353, -0.503, -0.938, all P<0.001). Whereas, a significantly positive correlation was found between serum Omentin-1 levels and high density lipoprotein cholesterol ( r=0.528, P<0.001). Omentin-1 concentrations were not related to age or gender ( r=-0.093, -0.040; P=0.669, 0.489). In multiple linear stepwise regression analysis, only VFA remained significantly associated with Omentin-1 ( β=-0.026, t=-2.250, P=0.026). Conclusion:The level of serum omentin-1 in patients with abdominal obesity was significantly lower than that in normal subjects, and it was closely related to body fat distribution and insulin resistance. VFA is an independent influencing factor of serum omentin-1, which can be used as a biomarker of abdominal obesity related metabolic disorders.